Dublin, March 08, 2018 -- The "Competent Cells Market - Global Opportunity Analysis and Industry Forecast (2018-2023)" report has been added to ResearchAndMarkets.com's offering.
"Global competent cells market is expected to reach USD 2,318.6 million by 2023, at a CAGR of 10.0% during the forecast period of 2018 to 2023."
Growing demand for recombinant proteins and molecular cloned products, advancement in molecular cloning research with emergence of new technologies, and various government initiatives and availability of funding for life science research are the key drivers propelling the industry growth during the forecast period. Moreover, emerging economies such as Latin America, Asia Pacific, & Africa provides significant opportunity in this market. However, factors such as high cost of cloning based research and shortage of skilled professionals for handling of competent cells hinder the growth of this market in many parts of the globe.
Transformation is a process which includes direct uptake of DNA released into an environment by host cells and simultaneously integrates that DNA with host genome for recombination. Naturally, many bacteria have an ability to take up DNA from environment. The DNA provides nutrients to these natural competent cells, while recombination leads to new genetic evolution.
This ability to take up external DNA is referred as natural competence. However, not all bacteria are naturally competent; thereby reduces the chances of recombinational development. Hence, by using this concept, researchers developed artificial competence, where the cells are made competent using induced methods such as electroporation or chemicals mediated methods.
The report also includes the competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 4 years (2014-2017).
Key questions answered in the report:
- Which are the high growth market segments in terms of product type, treatment, application, end user, and regions/countries?
- What is the historical market for competent cells across the globe?
- What are the market forecasts and estimates from the period 2018-2023?
- What are the major drivers, restraints, opportunities, and challenges in the global competent cells market?
- Who are the major players in the global competent cells market and what share of the market do they hold?
- Who are the major players in various countries and what share of the market do they hold?
- What are the competitive landscapes and who are the market leaders by sub-region in the global competent cells market?
- What are the recent developments in the global competent cells market?
- What are the different strategies adopted by the major players in the global competent cells market?
- What are the geographical trends and high growth regions/ countries?
- Who are the local emerging players in the global competent cells market and how do they compete with the global players?
Key Topics Covered:
1. Introduction
1.1. Market Ecosystem
1.2. Currency and Limitations
1.3. Key Stakeholders
2. Research Methodology
3. Executive Summary
4. Market insights
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Growing Demand for Recombinant Proteins & Molecular Cloned Products
4.2.1.2. Advancement in Molecular Cloning Research with Emergence of New Technologies
4.2.1.3. Rising Government Initiatives and Funding for Life Science Research
4.2.2. Restraints
4.2.2.1. High Cost of Cloning Based Research
4.2.2.2. Shortage of Skilled Professionals for Handling of Competent Cells
4.2.3. Opportunities
4.2.3.1. Emerging Markets: Asia Pacific, Africa and Latin America
4.2.4. Challenge
4.2.4.1. Complexities in Laboratory Transformation Parameters
5. Competent Cells Market, by Type
5.1. Introduction
5.2. Cloned Competent Cells
5.3. Expression Competent Cells
5.4. Agrobacterium Tumefaciens Competent Cells (Transformation)
6. Competent Cells Market, by Treatment
6.1. Introduction
6.2. Chemically Competent Cells
6.3. Electrocompetent Cells
7. Competent Cells Market, by Application
7.1. Introduction
7.2. Cloning
7.2.1. Subcloning and Routine Cloning
7.2.2. High-Throughput Cloning
7.2.3. Phage Display Library Production
7.2.4. Toxic/Unstable DNA Cloning
7.3. Protein Expression
7.4. Others
7.4.1. Single-Stranded DNA Preparation
7.4.2. Mutagenesis Study
7.4.3. Large Plasmid Transformation
7.4.4. Lentiviral Vector Production
8. Competent Cells Market, by End-User
8.1. Introduction
8.2. Pharmaceutical and Biotechnology industry
8.3. Academic and Research institutes
8.4. Contract Research organizations
9. Competent Cells Market, by Geography
10. Competitive Landscape
10.1. Introduction
10.2. Partnerships, Agreements, and Collaborations
10.3. Mergers and Acquisitions
10.4. New Product Launches and Upgradations
11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments)
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Cell Applications, Inc.
- Delphi Genetics S.A.
- GenScript Biotech Corporation
- Illumina, Inc.
- Merck & Co., Inc.
- Meridian Bioscience, Inc.
- New England Biolabs
- OriGene Technologies, Inc.
- Promega Corporation
- Qiagen N.V.
- Scarab Genomics, LLC
- Takara Holdings Inc.
- Thermo Fisher Scientific Inc.
- Zymo Research Corp
For more information about this report visit https://www.researchandmarkets.com/research/nq5cfs/global_competent?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biotechnology


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 



